Bridgewater Associates exited its position in BlackRock and cut exposure to two major U.S. banks while deploying $145.2 million into four assets that have doubled or more year-to-date, according to the fund's 13F filing disclosed this week. The rotation marks a clear shift from financial infrastructure into momentum names at a point when most family offices are still overweight quality dividend stocks.

The 13F shows Bridgewater eliminated its BlackRock stake entirely and reduced holdings in two unspecified U.S. banks. The freed capital moved into four positions that have each gained at least 100% in 2026. The filing does not name the specific assets, but the timing coincides with sharp moves in select technology infrastructure plays, certain commodity-linked equities, and a handful of biotech names that cleared Phase III trials in Q2. Bridgewater's total disclosed equity portfolio remains near $17 billion, and the rotation represents roughly 0.85% of AUM—material enough to signal conviction but sized as a satellite bet, not a core restructure.

The move matters because Bridgewater rarely chases momentum. The fund built its reputation on macro overlays and systematic rebalancing, not late-cycle rotations into parabolic names. The exit from BlackRock is particularly clean: the asset manager trades near all-time highs, and Bridgewater's timing suggests a view that flows into passive products are peaking or that fee compression will accelerate faster than the Street models. The bank cuts reinforce a thesis that net interest margin tailwinds are exhausted and credit quality is no longer improving. Meanwhile, the four high-momentum positions suggest Bridgewater sees a narrow set of winners extending gains into year-end, likely tied to themes that survive a higher-rate or no-landing scenario.

The catalog of 100%+ gainers in 2026 is short. Uranium producers, AI infrastructure plays, and GLP-1 supply chain stocks dominate the list. If Bridgewater leaned into any of those, it would align with the fund's public commentary on energy transition and healthcare innovation. The fund has historically rotated into momentum only when it sees a structural catalyst with at least 18-24 months of runway. That implies Dalio's team believes these names are midway through a re-rating, not at the top.

Operators should watch Bridgewater's next 13F in mid-August for position sizing changes and whether the momentum sleeve gets trimmed or expanded. The fund's allocation to cash and Treasury equivalents will clarify whether this is a broad risk-on pivot or a targeted rotation within equities. Family offices tracking the filing should also monitor BlackRock's Q2 flows, due in mid-July—if institutional redemptions accelerate, Bridgewater's exit looks prescient rather than tactical.

The four unnamed positions are now the most interesting line item in a portfolio that typically hides its alpha in bond futures and currency swaps. The 13F discloses the bet, but the thesis is still unreadable.